Chemotherapy and immunotherapy before possible surgery for mesothelioma
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving chemotherapy and immunotherapy before planned surgery can make inoperable pleural mesothelioma operable. It is for people with a specific type of mesothelioma (epithelioid) that cannot be removed right away, to see if the treatment shrinks the tumor enough for surgery later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of epithelioid pleural mesothelioma that cannot be surgically removed at first
- You must be 18 years or older
- You must be in good enough health to walk and do light activity (WHO performance status 0 or 1)
- You must be fit to receive chemotherapy, immunotherapy, and possibly surgery
- You must agree to use effective contraception if you could become pregnant or get a partner pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This trial studies a treatment plan that combines an immune drug (atezolizumab) and a personalized cancer vaccine (WT1/DC) with standard first-line chemotherapy for epithelioid malignant pleural mesothelioma that cannot be removed with surgery. It aims to improve control of the cancer by helping the immune system work alongside chemotherapy.
This Phase 2 study tests whether adding nivolumab (an immunotherapy) to a one-time “light-based” treatment during a lung procedure can control malignant pleural mesothelioma that can’t be surgically removed. You may be eligible if your cancer has come back or progressed after prior platinum chemotherapy, and if your tumor is reachable for the light treatment during thoracoscopy.
This trial tests adding immunotherapy before surgery to help patients with sarcomatoid pleural mesothelioma. The goal is to shrink or control the cancer and make surgery possible, while checking safety.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests whether more chemotherapy after surgery can help people with a specific type of abdominal cancer (malignant peritoneal mesothelioma). It is for those who have had all visible tumor removed and have not had chemotherapy before.
Hear when a new Neoadjuvant Chemoimmunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.